AT-001
Pioneering a path to treat rare & common forms of dementia
An oral treatment being designed to address rare and common forms of dementia by preventing and dissolving amyloid plaques and tau tangles.
-
55m+
People have dementia worldwide
-
10m
New cases diagnosed every year
-
€2.8T
Projected cost by 2030
Changing the dementia treatment paradigm
AT-001 is an oral treatment being designed to address rare and common forms of dementia by preventing and dissolving amyloid plaques and tau tangles. This is achieved by destabilizing the inter/intra-molecular interactions that form and maintain these detrimental aggregates. Hereditary cystatin C amyloid angiopathy (HCCAA) is a sub-type of cerebral amyloid angiopathy (CAA) – a cluster of hereditary forms of familial dementia, accounting for about 5% of all dementia in the world.
Our research signals that AT-001 could offer a novel disease-modifying approach, not only for HCCAA, but potentially for other forms of CAAs and protein aggregation disorders, where toxic oligomers are central to disease progression – such as Alzheimer’s disease.
To find out more about our clinical trials in an ultra-rare form of familial dementia, HCCAA, click here. To find our more about our clinical trials in Alzheimer’s disease, click here.
Hope in an unexpected place
Katrín Björk Guðjónsdóttir experienced multiple strokes by age 21 due to a rare familial genetic condition. Her personal story became the catalyst for AT-001’s development.
Dementia & Alzheimer’s disease present significant
challenges for individuals and their families.
These conditions are progressive and degenerative, leading to a decline in cognitive and functional
abilities over time. Some of the challenges faced by people with dementia and Alzheimer’s include:
-
Memory loss
One of the hallmark symptoms of dementia and Alzheimer’s is memory loss. Individuals may struggle to remember recent events or to retain new information, making it difficult to learn and engage in activities of daily living.
-
Communication difficulties
As the disease progresses, individuals may have difficulty communicating effectively, leading to frustration and isolation. They may struggle to find the right words, or to understand what others are saying, leading to misunderstandings and social withdrawal.
-
Behavioural changes
As the disease progresses, individuals may experience changes in mood and behavior, including agitation, aggression, and depression. These changes can be distressing for both the individual and their caregivers.
-
Caregiver burden
Caring for someone with dementia or Alzheimer’s can be challenging and demanding, both emotionally and physically. Caregivers may experience stress, burnout, and financial strain, and may struggle to balance their caregiving responsibilities with other obligations.
-
Social isolation
People with dementia and Alzheimer’s may experience social isolation and a loss of independence as their condition progresses. They may be
unable to participate in activities they once enjoyed, and may struggle to maintain social connections. -
Increased healthcare costs
Dementia and Alzheimer’s disease are associated with increased healthcare costs, including hospitalizations, long-term care, and medication
expenses. These costs can be a significant burden for individuals and families, as well as healthcare systems.
Explore more
For our latest news and updates, go check out
The Pulse. If you have additional questions for us or are interested in strategic partnering, contact us below.